

Kirsten GrÃ¶nbÃlk

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3130871/publications.pdf>

Version: 2024-02-01

148
papers

5,805
citations

76294

40
h-index

88593

70
g-index

153
all docs

153
docs citations

153
times ranked

9266
citing authors

#	ARTICLE	IF	CITATIONS
1	Epigenetic therapy in combination with a multi-epitope cancer vaccine targeting shared tumor antigens for high-risk myelodysplastic syndrome—A phase I clinical trial. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 433-444.	2.0	8
2	Expression patterns and prognostic potential of circular RNAs in mantle cell lymphoma: a study of younger patients from the MCL2 and MCL3 clinical trials. <i>Leukemia</i> , 2022, 36, 177-188.	3.3	11
3	Pre-treatment health-related quality of life parameters have prognostic impact in patients >65 years with newly diagnosed mantle cell lymphoma: The Nordic Lymphoma Group MCL4 (LENABERIT) experience. <i>Hematological Oncology</i> , 2022, 40, 23-31.	0.8	1
4	Humoral response to two doses of BNT162b2 vaccination in people with HIV. <i>Journal of Internal Medicine</i> , 2022, 291, 513-518.	2.7	33
5	Incidence of Positive Severe Acute Respiratory Syndrome Coronavirus Polymerase Chain Reaction After Coronavirus Disease 2019 Vaccination With up to 8 Months of Follow-up: Real-life Data From the Capital Region of Denmark. <i>Clinical Infectious Diseases</i> , 2022, 75, e675-e682.	2.9	7
6	Level of unique T cell clonotypes is associated with clonal hematopoiesis and survival in patients with lymphoma undergoing ASCT. <i>Bone Marrow Transplantation</i> , 2022, , .	1.3	1
7	Comprehensive and unbiased multiparameter high-throughput screening by compaRe finds effective and subtle drug responses in AML models. <i>ELife</i> , 2022, 11, .	2.8	2
8	Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q). <i>Leukemia</i> , 2022, 36, 1436-1439.	3.3	6
9	A predictive model for bone marrow disease in cytopenia based on noninvasive procedures. <i>Blood Advances</i> , 2022, 6, 3541-3550.	2.5	2
10	Inflammatory Cytokine Profiles Do Not Differ Between Patients With Idiopathic Cytopenias of Undetermined Significance and Myelodysplastic Syndromes. <i>HemaSphere</i> , 2022, 6, e0713.	1.2	3
11	Family caregiver ambassador support for caregivers of patients with newly diagnosed hematological cancer: a feasibility study. <i>Supportive Care in Cancer</i> , 2022, 30, 6923-6935.	1.0	8
12	The Thioredoxin-Interacting Protein TXNIP Is a Putative Tumour Suppressor in Cutaneous T-Cell Lymphoma. <i>Dermatology</i> , 2021, 237, 283-290.	0.9	8
13	Protein phosphatase, Mg ²⁺ /Mn ²⁺ -dependent 1D (PPM1D) mutations in haematological cancer. <i>British Journal of Haematology</i> , 2021, 192, 697-705.	1.2	7
14	Genome-Wide Circular RNA Expression Patterns Reflect Resistance to Immunomodulatory Drugs in Multiple Myeloma Cells. <i>Cancers</i> , 2021, 13, 365.	1.7	19
15	Risk of new malignancies among patients with CLL treated with chemotherapy: results of a Danish population-based study. <i>British Journal of Haematology</i> , 2021, 193, 339-345.	1.2	12
16	The Danish Myelodysplastic Syndromes Database: Patient Characteristics and Validity of Data Records. <i>Clinical Epidemiology</i> , 2021, Volume 13, 439-451.	1.5	5
17	Mutations known from B-cell lymphoid malignancies are not found in CD34 ⁺ stem cells from patients with lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 2808-2811.	0.6	1
18	Acute and persistent symptoms in non-hospitalized PCR-confirmed COVID-19 patients. <i>Scientific Reports</i> , 2021, 11, 13153.	1.6	147

#	ARTICLE	IF	CITATIONS
19	The Impact of Sedentary Lifestyle, High-fat Diet, Tobacco Smoke, and Alcohol Intake on the Hematopoietic Stem Cell Niches. <i>HemaSphere</i> , 2021, 5, e615.	1.2	5
20	Serum proteome modulations upon treatment provides biological insight on response to treatment in relapsed mantle cell lymphoma. <i>Cancer Reports</i> , 2021, , e1524.	0.6	1
21	The role of vitamin C in epigenetic cancer therapy. <i>Free Radical Biology and Medicine</i> , 2021, 170, 179-193.	1.3	23
22	A user's guide to multicolor flow cytometry panels for comprehensive immune profiling. <i>Analytical Biochemistry</i> , 2021, 627, 114210.	1.1	12
23	Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelomonocytic Leukemia: Clinical and Molecular Genetic Prognostic Factors in a Nordic Population. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 991.e1-991.e9.	0.6	6
24	Detailed Long-Term Follow-Up of Patients Who Relapsed After the Nordic Mantle Cell Lymphoma Trials: MCL2 and MCL3. <i>HemaSphere</i> , 2021, 5, e510.	1.2	18
25	TET2 mutations are associated with hypermethylation at key regulatory enhancers in normal and malignant hematopoiesis. <i>Nature Communications</i> , 2021, 12, 6061.	5.8	47
26	Structural aberrations are associated with poor survival in patients with clonal cytopenia of undetermined significance. <i>Haematologica</i> , 2021, 106, 1762-1766.	1.7	6
27	Level of Unique T-Cell Clonotypes Are Associated with Clonal Hematopoiesis and Survival in Patients with Lymphoma Intended for Autologous Stem Cell Transplant. <i>Blood</i> , 2021, 138, 3942-3942.	0.6	0
28	<i>KMT2D</i> mutations and <i>TP53</i> disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study. <i>Haematologica</i> , 2020, 105, 1604-1612.	1.7	96
29	The diagnostic and prognostic role of flow cytometry in idiopathic and clonal cytopenia of undetermined significance (ICUS/CCUS): A single-center analysis of 79 patients. <i>Cytometry Part B - Clinical Cytometry</i> , 2020, 98, 250-258.	0.7	10
30	Cell of origin determined by both gene expression profiling and immunohistochemistry is the strongest predictor of survival in patients with diffuse large B-cell lymphoma. <i>American Journal of Hematology</i> , 2020, 95, 57-67.	2.0	27
31	Human endogenous retroviruses form a reservoir of T cell targets in hematological cancers. <i>Nature Communications</i> , 2020, 11, 5660.	5.8	55
32	p53 is associated with high-risk and pinpoints <i>TP53</i> missense mutations in mantle cell lymphoma. <i>British Journal of Haematology</i> , 2020, 191, 796-805.	1.2	31
33	Identification of unique and shared mitochondrial DNA mutations in neurodegeneration and cancer by single-cell mitochondrial DNA structural variation sequencing (MitoSV-seq). <i>EBioMedicine</i> , 2020, 57, 102868.	2.7	11
34	Activation of a Subset of Evolutionarily Young Transposable Elements and Innate Immunity Are Linked to Clinical Responses to 5-Azacytidine. <i>Cancer Research</i> , 2020, 80, 2441-2450.	0.4	33
35	Clonal hematopoiesis evolves from pretreatment clones and stabilizes after end of chemotherapy in patients with MCL. <i>Blood</i> , 2020, 135, 2000-2004.	0.6	26
36	The value of circulating microRNAs for early diagnosis of B-cell lymphoma: A case-control study on historical samples. <i>Scientific Reports</i> , 2020, 10, 9637.	1.6	10

#	ARTICLE	IF	CITATIONS
37	Clinical impact of clonal hematopoiesis in patients with lymphoma undergoing ASCT: a national population-based cohort study. <i>Leukemia</i> , 2020, 34, 3256-3268.	3.3	46
38	Angiotensinogen promoter methylation predicts bevacizumab treatment response of patients with recurrent glioblastoma. <i>Molecular Oncology</i> , 2020, 14, 964-973.	2.1	2
39	Improved Outcomes after Allogenic Hematopoietic Stem Cell Transplantation with Fludarabine/Treosulfan for Patients with Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1091-1098.	2.0	7
40	Clonal hematopoiesis in elderly twins: concordance, discordance, and mortality. <i>Blood</i> , 2020, 135, 261-268.	0.6	47
41	Profiling of ribose methylations in ribosomal RNA from diffuse large B-cell lymphoma patients for evaluation of ribosomes as drug targets. <i>NAR Cancer</i> , 2020, 2, zcaa035.	1.6	29
42	Pre-Treatment Health-Related Quality of Life Parameters May Have Prognostic Impact in Elderly Patients with Mantle Cell Lymphoma. the Nordic Lymphoma Group MCL4 (LENA-BERIT) Experience. <i>Blood</i> , 2020, 136, 8-9.	0.6	0
43	Therapeutic Cancer Vaccination Targeting Shared Tumor Associated Antigens in Combination with Azacitidine for High Risk Myelodysplastic Syndrome - a Phase I Clinical Trial. <i>Blood</i> , 2020, 136, 23-24.	0.6	2
44	Oral vitamin C supplementation to patients with myeloid cancer on azacitidine treatment: Normalization of plasma vitamin C induces epigenetic changes. <i>Clinical Epigenetics</i> , 2019, 11, 143.	1.8	55
45	Increased neonatal level of arginase 2 in cases of childhood acute lymphoblastic leukemia implicates immunosuppression in the etiology. <i>Haematologica</i> , 2019, 104, e514-e516.	1.7	8
46	Epigenetic therapy in hematological cancers. <i>Apmis</i> , 2019, 127, 316-328.	0.9	16
47	Nordic Guidelines for Germline Predisposition to Myeloid Neoplasms in Adults: Recommendations for Genetic Diagnosis, Clinical Management and Follow-up. <i>HemaSphere</i> , 2019, 3, e321.	1.2	51
48	Expression of CRBN, IKZF1, and IKZF3 does not predict lenalidomide sensitivity and mutations in the cereblon pathway are infrequent in multiple myeloma. <i>Leukemia and Lymphoma</i> , 2019, 60, 180-188.	0.6	26
49	A Circular RNA Molecule, circRAB11FIP1, Is Associated with TP53 Mutations and Is of Potential Prognostic and Functional Significance in Mantle Cell Lymphoma: Data from the Nordic MCL2 and MCL3 Studies. <i>Blood</i> , 2019, 134, 1495-1495.	0.6	1
50	Diagnostic 2-Gene Classifier in Early-Stage Mycosis Fungoides: A Retrospective Multicenter Study. <i>Blood</i> , 2019, 134, 2772-2772.	0.6	0
51	Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial. <i>Lancet Haematology</i> , 2018, 5, e109-e116.	2.2	117
52	Vitamin C – A new player in regulation of the cancer epigenome. <i>Seminars in Cancer Biology</i> , 2018, 51, 59-67.	4.3	73
53	Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon-independent manner. <i>Molecular Oncology</i> , 2018, 12, 180-195.	2.1	62
54	Mother-child transmission of epigenetic information by tunable polymorphic imprinting. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E11970-E11977.	3.3	33

#	ARTICLE	IF	CITATIONS
55	Epidemiology of chronic red blood cell transfusion recipients in Sweden and Denmark—a 10 year follow-up study. <i>Vox Sanguinis</i> , 2018, 113, 770-778.	0.7	0
56	Human adult HSCs can be discriminated from lineage-committed HPCs by the expression of endomucin. <i>Blood Advances</i> , 2018, 2, 1628-1632.	2.5	10
57	Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma. <i>Haematologica</i> , 2018, 103, e541-e543.	1.7	19
58	DNA Methylation Levels of the ELMO Gene Promoter CpG Islands in Human Glioblastomas. <i>International Journal of Molecular Sciences</i> , 2018, 19, 679.	1.8	19
59	Long-term clinical outcomes of patients with hematologically unexplained cytopenia after routine assessment: A single center study. <i>European Journal of Haematology</i> , 2018, 101, 595-603.	1.1	4
60	Long Non-Coding RNAs Guide the Fine-Tuning of Gene Regulation in B-Cell Development and Malignancy. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2475.	1.8	33
61	Enzyme-free digital counting of endogenous circular RNA molecules in B-cell malignancies. <i>Laboratory Investigation</i> , 2018, 98, 1657-1669.	1.7	93
62	Phase I Results of a Multicenter Clinical Trial Combining Guadecitabine, a DNA Methyltransferase Inhibitor, with Atezolizumab, an Immune Checkpoint Inhibitor, in Patients with Relapsed or Refractory Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia. <i>Blood</i> , 2018, 132, 1811-1811.	0.6	7
63	Nucleosome Positioning and NDR Structure at RNA Polymerase III Promoters. <i>Scientific Reports</i> , 2017, 7, 41947.	1.6	29
64	Anemia is present years before myelodysplastic syndrome diagnosis: Results from the pre-diagnostic period. <i>American Journal of Hematology</i> , 2017, 92, E130-E132.	2.0	5
65	Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and Tj ETQq1 1 0.784314 rgBT /Overlo 428-435.	2.0	36
66	TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. <i>Blood</i> , 2017, 130, 1903-1910.	0.6	296
67	DNA Methyltransferase Inhibitors in Myeloid Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2017, 23, 277-285.	1.0	6
68	Epigenetic changes in myelofibrosis: Distinct methylation changes in the myeloid compartments and in cases with ASXL1 mutations. <i>Scientific Reports</i> , 2017, 7, 6774.	1.6	16
69	Mature lymphoid malignancies: origin, stem cells, and chronicity. <i>Blood Advances</i> , 2017, 1, 2444-2455.	2.5	13
70	Immune Mechanisms in Myelodysplastic Syndrome. <i>International Journal of Molecular Sciences</i> , 2016, 17, 944.	1.8	48
71	Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma. <i>Blood</i> , 2016, 128, 1814-1820.	0.6	75
72	Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma. <i>Blood</i> , 2016, 128, 2666-2670.	0.6	82

#	ARTICLE	IF	CITATIONS
73	15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (<sc>MCL</sc>): prolonged remissions without survival plateau. <i>British Journal of Haematology</i> , 2016, 175, 410-418.	1.2	170
74	Vitamin C increases viral mimicry induced by 5-aza-2'-deoxycytidine. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 10238-10244.	3.3	171
75	Mutations in idiopathic cytopenia of undetermined significance assist diagnostics and correlate to dysplastic changes. <i>American Journal of Hematology</i> , 2016, 91, 1234-1238.	2.0	32
76	TP53 hotspot mutations are predictive of survival in primary central nervous system lymphoma patients treated with combination chemotherapy. <i>Acta Neuropathologica Communications</i> , 2016, 4, 40.	2.4	19
77	Assessment of Quantitative and Allelic MGMT Methylation Patterns as a Prognostic Marker in Glioblastoma. <i>Journal of Neuropathology and Experimental Neurology</i> , 2016, 75, 246-255.	0.9	33
78	Molecular Monitoring and Tailored Strategy with Pre-Emptive Rituximab Treatment for Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-up of 8.5 Years. <i>Blood</i> , 2016, 128, 146-146.	0.6	4
79	Ibrutinib-Lenalidomide-Rituximab in Patients with Relapsed/Refractory Mantle Cell Lymphoma: First Results from the Nordic Lymphoma Group MCL6 (PHILEMON) Phase II Trial. <i>Blood</i> , 2016, 128, 148-148.	0.6	12
80	Tumor suppressor microRNAs are downregulated in myelodysplastic syndrome with spliceosome mutations. <i>Oncotarget</i> , 2016, 7, 9951-9963.	0.8	27
81	IRF1 Deletions: A Novel Marker of Clinical Aggressiveness in Primary Mediastinal B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 609-609.	0.6	0
82	Cereblon Is Downregulated By Promoter Nucleosome Occupancy in Acquired IMiD Resistance: The Potential of IMiD Resensitization By Epigenetic Therapy. <i>Blood</i> , 2016, 128, 3258-3258.	0.6	0
83	Increased Risk of Second Hematological and Non-Hematological Malignancies in CLL Patients Treated with Chemotherapy As Compared to Untreated Patients and Matched Controls - Results from a Danish Population Based Study. <i>Blood</i> , 2016, 128, 3219-3219.	0.6	0
84	Loss of PRDM11 promotes MYC-driven lymphomagenesis. <i>Blood</i> , 2015, 125, 1272-1281.	0.6	18
85	miR-18b overexpression identifies mantle cell lymphoma patients with poor outcome and improves the MIPI-B prognosticator. <i>Blood</i> , 2015, 125, 2669-2677.	0.6	44
86	Whole-exome sequencing and genome-wide methylation analyses identify novel disease associated mutations and methylation patterns in idiopathic hypereosinophilic syndrome. <i>Oncotarget</i> , 2015, 6, 40588-40597.	0.8	14
87	Hypermethylation of the VTRNA1-3 Promoter is Associated with Poor Outcome in Lower Risk Myelodysplastic Syndrome Patients. <i>Genes</i> , 2015, 6, 977-990.	1.0	19
88	Development and Blind Clinical Validation of a MicroRNA Based Predictor of Response to Treatment with R-CHO(E)P in DLBCL. <i>PLoS ONE</i> , 2015, 10, e0115538.	1.1	19
89	DNA Methylation and Hydroxymethylation in Cancer. , 2015, , 9-30.		4
90	Differential Expression of miR-155 and miR-21 in Tumor and Stroma Cells in Diffuse Large B-Cell Lymphoma. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2015, 23, 188-195.	0.6	10

#	ARTICLE	IF	CITATIONS
91	Allele-Specific DNA Methylation Detection by Pyrosequencing®. <i>Methods in Molecular Biology</i> , 2015, 1315, 271-289.	0.4	5
92	Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation. <i>Oncotarget</i> , 2015, 6, 9612-9626.	0.8	166
93	A novel del(8)(q23.2q24.11) contributing to disease progression in a case of JAK2/TET2 double mutated chronic myelomonocytic leukemia. <i>Leukemia Research Reports</i> , 2014, 3, 94-97.	0.2	1
94	Validation of a diagnostic microRNA classifier in cutaneous T-cell lymphomas. <i>Leukemia and Lymphoma</i> , 2014, 55, 957-958.	0.6	28
95	SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma – a Nordic Lymphoma Group study. <i>British Journal of Haematology</i> , 2014, 166, 98-108.	1.2	110
96	A Dual Program for Translation Regulation in Cellular Proliferation and Differentiation. <i>Cell</i> , 2014, 158, 1281-1292.	13.5	414
97	Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat. <i>Leukemia Research</i> , 2014, 38, 816-821.	0.4	12
98	Predicting response to epigenetic therapy. <i>Journal of Clinical Investigation</i> , 2014, 124, 47-55.	3.9	78
99	Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma. <i>Blood</i> , 2014, 123, 2953-2959.	0.6	90
100	MicroRNA expression in early mycosis fungoides is distinctly different from atopic dermatitis and advanced cutaneous T-cell lymphoma. <i>Anticancer Research</i> , 2014, 34, 7207-17.	0.5	55
101	MicroRNAs in mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2013, 54, 1867-1875.	0.6	11
102	Somatic mutations of the CREBBP and EP300 genes affect response to histone deacetylase inhibition in malignant DLBCL clones. <i>Leukemia Research Reports</i> , 2013, 2, 1-3.	0.2	30
103	Kinetics of del(7q) driven leukemogenesis in a patient with JAK2 V617F and TET2 mutated chronic myeloproliferative neoplasm. <i>Leukemia Research Reports</i> , 2013, 2, 51-53.	0.2	1
104	Downregulation but lack of promoter hypermethylation or somatic mutations of the potential tumor suppressor CXXC5 in MDS and AML with deletion 5q. <i>European Journal of Haematology</i> , 2013, 90, 259-260.	1.1	17
105	Analysis of Epigenetic Modifications of DNA in Human Cells. <i>Current Protocols in Human Genetics</i> , 2013, 77, Unit20.2.	3.5	9
106	Aberrant microRNA expression in multiple myeloma. <i>European Journal of Haematology</i> , 2013, 91, 95-105.	1.1	40
107	Clonal expansion of renal cell carcinoma-infiltrating T lymphocytes. <i>Oncolmmunology</i> , 2013, 2, e26014.	2.1	20
108	Tubulointerstitial Nephritis in a Patient With Probable Autoimmune Lymphoproliferative Syndrome. <i>Journal of Pediatric Hematology/Oncology</i> , 2013, 35, e187-e189.	0.3	4

#	ARTICLE	IF	CITATIONS
109	Investigation of MGMT and DAPK1 methylation patterns in diffuse large B-cell lymphoma using allelic MSP-pyrosequencing. <i>Scientific Reports</i> , 2013, 3, 2789.	1.6	30
110	MicroRNA Profiling in Ocular Adnexal Lymphoma: A Role for MYC and NFKB1 Mediated Dysregulation of MicroRNA Expression in Aggressive Disease. , 2013, 54, 5169.		27
111	Genome-wide profiling identifies a DNA methylation signature that associates with TET2 mutations in diffuse large B-cell lymphoma. <i>Haematologica</i> , 2013, 98, 1912-1920.	1.7	116
112	Lenalidomide, Bendamustine, and Rituximab As First-Line Therapy For Patients >65 Years With Mantle Cell Lymphoma: Preliminary Results From The Nordic Lymphoma Group MCL4 (LENA-BERIT) Phase I-II Trial. <i>Blood</i> , 2013, 122, 4377-4377.	0.6	11
113	Diffuse Large B-Cell Lymphoma With Combined TP53 mutation and MIR34A methylation: Another "double hit" Lymphoma With Very Poor Outcome?. <i>Blood</i> , 2013, 122, 83-83.	0.6	9
114	A critical appraisal of tools available for monitoring epigenetic changes in clinical samples from patients with myeloid malignancies. <i>Haematologica</i> , 2012, 97, 1380-1388.	1.7	20
115	Allelic methylation levels of the noncoding VTRNA2-1 located on chromosome 5q31.1 predict outcome in AML. <i>Blood</i> , 2012, 119, 206-216.	0.6	97
116	Lack of somatic mutations in the catalytic domains of CREBBP and EP300 genes implies a role for histone deacetylase inhibition in myeloproliferative neoplasms. <i>Leukemia Research</i> , 2012, 36, 485-487.	0.4	6
117	miR34s in Normal and Malignant B-Cells: miR34A Plays a Dominant Role in Normal B-Cells, and aggressive Diffuse Large B-Cell Lymphoma Carry Combined Lesions of TP53, MIR34A, and MIR34B/C. <i>Blood</i> , 2012, 120, 296-296.	0.6	1
118	Nordic MCL3 Study: Zevalin Combined with High-Dose Chemotherapy Followed by Autologous Stem Cell Support As Late Intensification for Mantle Cell Lymphoma (MCL) Patients < 66 Years Not in CR After Induction Chemoimmunotherapy: No Benefit of Zevalin. <i>Blood</i> , 2012, 120, 747-747.	0.6	3
119	miRNA Profiling Predicts Survival and Identifies a Novel Putative Oncomir in Diffuse Large B-Cell Lymphoma Treated with Immunochemotherapy. <i>Blood</i> , 2012, 120, 1548-1548.	0.6	0
120	MicroRNA Profiling in Low-Grade Ocular MALT and Diffuse Large B-Cell Lymphoma: A Role for MYC and NFKB1 Mediated Dysregulation of MicroRNA Expression in Aggressive Disease. <i>Blood</i> , 2012, 120, 1600-1600.	0.6	0
121	Allelic Methylation Levels of VTRNA2-1 Predict Outcome in Higher Risk MDS Patients Not Treated by Azacytidine.. <i>Blood</i> , 2012, 120, 2394-2394.	0.6	0
122	Advances in DNA methylation: 5-hydroxymethylcytosine revisited. <i>Clinica Chimica Acta</i> , 2011, 412, 831-836.	0.5	93
123	MicroRNA-130a-mediated down-regulation of Smad4 contributes to reduced sensitivity to TGF- β 1 stimulation in granulocytic precursors. <i>Blood</i> , 2011, 118, 6649-6659.	0.6	53
124	Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities. <i>Haematologica</i> , 2011, 96, 963-971.	1.7	52
125	miR-449 inhibits cell proliferation and is down-regulated in gastric cancer. <i>Molecular Cancer</i> , 2011, 10, 29.	7.9	206
126	Diagnostic microRNA profiling in cutaneous T-cell lymphoma (CTCL). <i>Blood</i> , 2011, 118, 5891-5900.	0.6	237

#	ARTICLE	IF	CITATIONS
127	Lenalidomide, Bendamustine, and Rituximab As First-Line Therapy for Patients > 65 Years with Mantle Cell Lymphoma: Results From the Phase I Portion of the Nordic Lymphoma Group MCL4 (LENA-BERIT) Trial. <i>Blood</i> , 2011, 118, 2700-2700.	0.6	12
128	Mir-130a-Mediated Downregulation of SMAD4 Contributes to Reduced Sensitivity to TGF β 2 Stimulation in Promyelocytic Cells. <i>Blood</i> , 2011, 118, 3383-3383.	0.6	0
129	Allelic Methylation Levels of the Non-Coding RNA Gene VTRNA2-1 Located on Chromosome 5q31.1 Predict Outcome in AML. <i>Blood</i> , 2011, 118, 3450-3450.	0.6	0
130	TET2 mutations in Diffuse Large B-Cell Lymphoma: The Role of TET2 in the Regulation of Methylation Patterns at TET2 Target Genes. <i>Blood</i> , 2011, 118, 1364-1364.	0.6	0
131	Deficient SOCS3 and SHP-1 Expression in Psoriatic T Cells. <i>Journal of Investigative Dermatology</i> , 2010, 130, 1590-1597.	0.3	40
132	Cancer Risk in Long-term Users of Valproate: A Population-Based Case-Control Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 1714-1719.	1.1	28
133	Splenectomy in two children with autoimmune lymphoproliferative syndrome and massive splenomegaly. <i>Pediatric Blood and Cancer</i> , 2009, 53, 1124-1126.	0.8	1
134	Engaging the lysosomal compartment to combat B cell malignancies. <i>Journal of Clinical Investigation</i> , 2009, 119, 2133-6.	3.9	5
135	A novel splice mutation in the TP53 gene associated with Leydig cell tumor and primitive neuroectodermal tumor. <i>Pediatric Blood and Cancer</i> , 2008, 50, 701-703.	0.8	6
136	Epigenetic Changes in Cancer as Potential Targets for Prophylaxis and Maintenance Therapy. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2008, 103, 389-396.	1.2	26
137	Frequent hypermethylation of DBC1 in malignant lymphoproliferative neoplasms. <i>Modern Pathology</i> , 2008, 21, 632-638.	2.9	22
138	Epigenetic changes in cancer. <i>Apmis</i> , 2007, 115, 1039-1059.	0.9	320
139	MicroRNAs and cancer. <i>Apmis</i> , 2007, 115, 1090-1106.	0.9	162
140	Genetic and epigenetic alterations of the reduced folate carrier in untreated diffuse large B-cell lymphoma. <i>European Journal of Haematology</i> , 2007, 80, 071119183417001-???	1.1	13
141	Microarray-based classification of diffuse large B-cell lymphoma. <i>European Journal of Haematology</i> , 2005, 74, 453-465.	1.1	42
142	Genetic and epigenetic alterations of the APC gene in malignant melanoma. <i>Oncogene</i> , 2004, 23, 5215-5226.	2.6	105
143	Aberrations of the Chk2 tumour suppressor in advanced urinary bladder cancer. <i>Oncogene</i> , 2004, 23, 8545-8551.	2.6	42
144	Infrequent somatic Fas mutations but no evidence of Bcl10 mutations or t(11;18) in primary cutaneous MALT-type lymphoma. <i>Journal of Pathology</i> , 2003, 201, 134-140.	2.1	30

#	ARTICLE	IF	CITATIONS
145	ATM mutations are associated with inactivation of the ARF-TP53 tumor suppressor pathway in diffuse large B-cell lymphoma. <i>Blood</i> , 2002, 100, 1430-1437.	0.6	78
146	Profiling DNA methylation by melting analysis. <i>Methods</i> , 2002, 27, 121-127.	1.9	46
147	Mutational analysis of the tumour suppressor gene MMAC1/PTEN in malignant myeloid disorders. <i>European Journal of Haematology</i> , 2000, 65, 109-113.	1.1	64
148	Detection of mutations in GC-rich DNA by bisulphite denaturing gradient gel electrophoresis. <i>Nucleic Acids Research</i> , 1998, 26, 1548-1549.	6.5	27